Kiora Pharmaceuticals, Inc.
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • Contact
Kiora Pharmaceuticals, Inc.
  • About
  • Technology
    • KIO-101
    • KIO-201
    • KIO-301
  • Pipeline
  • Investors & News
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Signup
Contact MENU

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • Email Signup
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
Oct 15, 2015 8:30am EDT

EyeGate Pharma Receives USPTO Notice of Allowance for Next Generation of Proprietary Iontophoretic Delivery System

Sep 01, 2015 8:30am EDT

Eyegate Pharmaceuticals to Present at the 17th Rodman and Renshaw 2015 Annual Global Investment Conference

Aug 05, 2015 1:30pm EDT

Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants

Jul 30, 2015 6:08pm EDT

EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants

Jul 24, 2015 8:30am EDT

EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation

Jul 14, 2015 8:30am EDT

EyeGate Pharma Treats First Patient in Phase 1b / 2a Trial of EGP-437 in Macular Edema

Jul 10, 2015 8:30am EDT

EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis

May 04, 2015 8:30am EDT

EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis

Mar 31, 2015 5:40pm EDT

EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results

Mar 02, 2015 8:30am EST

Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer

  • arrow_back
  • 1…
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Kiora Pharmaceuticals, Inc.
332 Encinitas Boulevard
Suite 102
Encinitas, CA 92024
info@kiorapharma.com
Twitter LinkedIn
©2023 Kiora Pharmaceuticals, Inc.
AboutManagement TeamBoard of DirectorsScientific Advisory BoardTechnologyKIO-101KIO-201KIO-301Pipeline
Investors Overview News & Events Company Info Financial Info Stock Data SEC Filings Governance Email Signup
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie Duration Description
cookielawinfo-checkbox-analytics 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional 11 months The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary 11 months This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy 11 months The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT